Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on ...

Travere Therapeutics, Inc. is rated Buy with FILSPARI’s robust growth, FDA approval, and key milestones ahead. Click here to ...

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Learn more about whether ACADIA Pharmaceuticals Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

On 12 September 2025, Hoffmann-La Roche conducted a study is to assess the efficacy, safety, and pharmacokinetics ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Stifel raised the firm’s price target on Travere Therapeutics (TVTX) to $25 from $20 and keeps a Hold rating on the shares following the ...

Travere Therapeutics (TVTX) is down -6.6%, or -$1.79 to $25.52. Published first on TheFly – the ultimate source for real-time, market-moving ...

CarMax reports that the Chevrolet Traverse excels in space and tech, while the Honda Pilot offers superior driving experience ...

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation, joined by more than 50 advocates living with rare kidney diseases, are convening on Capitol Hill to rally support for policy ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.